TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)


Chi K. N. , Chowdhury S., Radziszewski P., Lebret T., Ozguroglu M., Sternberg C., ...More

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 27
  • Doi Number: 10.1093/annonc/mdw372.54
  • City: Copenhagen
  • Country: Denmark